| 1. |
Tanaka Y, Ito T, Murata M, Tanegashima K, Kaku-Ito Y, Nakahara T. , NECTIN4-targeted antibody-drug conjugate is a potential therapeutic option for extramammary Paget disease. , Exp Dermatol, 33(3):e15049. doi: 10.1111/exd.15049. , 2024.03. |
| 2. |
Ito T, Tanaka Y, Kaku-Ito Y, Oda Y, Nakahara T. , FOXM1: a new therapeutic target of extramammary Paget disease., Sci Rep, 14(1):4048. doi: 10.1038/s41598-024-54773-8, 2024.02. |
| 3. |
Ito T, Kaku-Ito Y, Ohno F, Nakahara T., A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan, Front Med (Lausanne). , 10:1293397. doi:, 2023.11. |
| 4. |
Ito T, Tanaka Y, Ichiki T, Kaku-Ito Y, Nakahara T., KS-EMPD-1: a novel cell line of primary extramammary Paget's disease, Hum Cell., 10.1007/s13577-023-00951-1., 1813-1829, 36(5), 2023.09. |
| 5. |
Ito T, Hashimoto H, Kaku-Ito Y, Tanaka Y, Nakahara T., Nail Apparatus Melanoma: Current Management and Future Perspectives, J Clin Med., 12(6):2203., 2023.03. |
| 6. |
Tanaka Y, Ito T, Kaku-Ito Y, Tanegashima K, Tsuji G, Kido-Nakahara M, Oda Y, Nakahara T., Human epidermal growth factor receptor 3 serves as a novel therapeutic target for acral melanoma, Cell Death Discov. , 9(1):54., 2023.02. |
| 7. |
Hsieh CC, Su YC, Jiang KY, Ito T, Li TW, Kaku-Ito Y, Cheng ST, Chen LT, Hwang DY, Shen CH., TRPM1 promotes tumor progression in acral melanoma by activating the Ca2+/CaMKIIδ/AKT pathway, J Adv Res., 43:45-57., 2023.01. |
| 8. |
Ito T, Hashimoto H, Tanaka Y, Tanegashima K, Murata M, Oda Y, Kaku-Ito Y., NECTIN4 expression in sebaceous and sweat gland carcinoma., Eur J Dermatol., 32(2):181-186, 2022.04. |
| 9. |
Kaku-Ito Y, Ito T, Tsuji G, Nakahara T, Hagihara A, Furue M, Uchi H. , Evaluation of mapping biopsies for extramammary Paget disease: A retrospective study. , J Am Acad Dermatol. , 78(6):1171-1177.e4., 2018.06. |
| 10. |
Ito T, Kaku-Ito Y, Murata M, Ichiki T, Kuma Y, Tanaka Y, Ide T, Ohno F, Wada-Ohno M, Yamada Y, Oda Y, Furue M. , Intra- and Inter-Tumor BRAF Heterogeneity in Acral Melanoma: An Immunohistochemical Analysis. , Int J Mol Sci. , 20(24):6191., 2019.12. |
| 11. |
Ito T, Kaku-Ito Y, Murata M, Furue K, Shen CH, Oda Y, Furue M. , Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival. , J Clin Med., 9(3):690. , 2020.03. |
| 12. |
Ito T, Kaku-Ito Y, Wada-Ohno M, Furue M. , Narrow-Margin Excision for Invasive Acral Melanoma: Is It Acceptable? , J Clin Med., 9(7):2266. , 2020.07. |
| 13. |
Murata M, Ito T, Tanaka Y, Kaku-Ito Y, Furue M. , NECTIN4 Expression in Extramammary Paget's Disease: Implication of a New Therapeutic Target., Int J Mol Sci. , 21(16):5891. , 2020.08. |
| 14. |
Ito T, Tanaka Y, Murata M, Kaku-Ito Y, Furue K, Furue M. , BRAF Heterogeneity in Melanoma. , Curr Treat Options Oncol., 22(3):20., 2021.02. |
| 15. |
Hashimoto H, Kaku-Ito Y, Furue M, Ito T. , The Outcome of Chemotherapy for Metastatic Extramammary Paget's Disease. , J Clin Med. , 10(4):739. , 2021.02. |
| 16. |
Hashimoto H, Kaku-Ito Y, Furue M, Ito T. , Mucosal Invasion, but Not Incomplete Excision, Has Negative Impact on Long-Term Survival in Patients With Extramammary Paget's Disease. , Front Oncol., 11:642919. , 2021.04. |
| 17. |
Ito T, Tanegashima K, Tanaka Y, Hashimoto H, Murata M, Oda Y, Kaku-Ito Y., Trop2 Expression in Extramammary Paget's Disease and Normal Skin. , Int J Mol Sci., 22(14):7706., 2021.07. |
| 18. |
Hashimoto H, Kaku-Ito Y, Oda Y, Ito T. , CDK4: A Novel Therapeutic Target for Extramammary Paget's Disease. , Front Oncol., 11:710378., 2021.07. |
| 19. |
Ito T, Hashimoto H, Tanaka Y, Tanegashima K, Murata M, Ichiki T, Iwasaki T, Oda Y, Kaku-Ito Y. , TROP2 Expression in Sebaceous and Sweat Gland Carcinoma., J Clin Med., 11(3):607. , 2022.01. |
